PDCD1 and non-small cell lung carcinoma: The KEYNOTE-024 study was the first to demonstrate an OS benefit with anti-PD-1 monotherapy compared to platinum-based chemotherapy as first-line treatment in patients with advanced NSCLC, thereby changing the treatment paradigm for this disease.